Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21954905 | 0.84 | LRRK2 (0.43) | MEN1KMT2AHTR2AHTR2CDDB1 | |
| SCHEMBL21958443 | 0.78 | MEN1 (0.48) | MEN1KMT2AGRM5HTR2COPRD1 | |
| SCHEMBL21939251 | 0.78 | MEN1 (0.54) | MEN1KMT2AGRM5DDB1CRBN | |
| SCHEMBL21954898 | 0.78 | LRRK2 (0.41) | MEN1KMT2ADDB1CRBNDRD3 | |
| SCHEMBL23865260 | 0.75 | MEN1 (0.54) | MEN1KMT2AGRM5DDB1CRBN | |
| SCHEMBL30038949 | 0.75 | MEN1 (0.50) | MEN1KMT2AGRM5AOC3DRD2 | |
| SCHEMBL13637297 | 0.72 | GRM5 (0.54) | MEN1KMT2AGRM5OPRD1DDB1 | |
| SCHEMBL19368987 | 0.72 | MEN1 (0.50) | MEN1KMT2AGRM5OPRD1DDB1 | |
| SCHEMBL8227244 | 0.72 | MEN1 (0.62) | MEN1KMT2AGRM5OPRD1DDB1 | |
| SCHEMBL31743068 | 0.71 | GRM5 (0.56) | MEN1KMT2AGRM5HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210347772-A1 | AZAINDOLE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347772-A1 | AZAINDOLE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | LRRK2, PARK7, GDI2 | MEN1 2367/4885KMT2A 456/4885GRM5 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.